Quality of Life Study in Adults With Facial Eczema
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This study is not being conducted in the US.
The study consists of a 4 week double blind treatment period. All patients meeting the
inclusion/exclusion criteria will enter the study at day 0 and be randomized into either
pimecrolimus cream 1% or vehicle treatment groups in a 1:1 ratio. Patients will return to
clinic on days 7,14 and 28 for assessments of disease severity. Patients who experience an
unsatisfactory therapeutic effect, will attend an unscheduled visit and be withdrawn from the
study.
Assessments of eligibility include an Investigator's Global Assessment and Pruritus score.
Treatment history will be collected at baseline and Quality of Life Questionnaires will be
carried out at every visit.